According to a major international study, Switzerland has once again fallen behind other European countries in terms of access to new innovative medicines – from sixth to seventh place. Particularly worrying is the fact that, compared to Germany, only around half as many new innovative medicines are reimbursed as standard via the specialty list.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Early rheumatoid arthritis
C1M has potential as a biomarker
- Osteoporosis
Risk-stratified therapy with osteoanabolic agents improves outcomes
- "Swiss Health Care Atlas"
New indicator: medication for weight regulation
- AI in neurology
Control instead of a flood of data: AI makes big data and wearables usable
- Longevity Medicine 2025
From anti-ageing to precision prevention
- Treatment of pancreatitis: current study data
How can the risk-benefit profile be improved?
- Prurigo and PN
Anti-inflammatory antipruritic therapy improves quality of life
- Pathophysiology, clinical significance and therapeutic consequences